The UN Treaty Bottleneck: Cannabis's Long Road Out of Schedule I

October 8, 2026

Photo by 995645 via Pixabay.

Scroll through US cannabis headlines from early 2026 and you'd be forgiven for thinking the plant had finally shed its outlaw status everywhere. The April 22 move from Acting Attorney General Todd Blanche shifting FDA-approved and state-licensed medical marijuana to Schedule III landed with the kind of coverage usually reserved for major court rulings. But step outside the US regulatory frame and the picture barely moves. Cannabis is still sitting in Schedule I of the Single Convention on Narcotic Drugs, the foundational UN treaty that both the US and 182 other countries are bound by. Domestic rescheduling is real. International rescheduling is not happening, and the reasons why are worth understanding on their own terms.

The clearest evidence of how stuck cannabis is came in December 2020, when the Commission on Narcotic Drugs voted to pull cannabis out of Schedule IV -- the harshest tier, reserved for substances deemed to have no medical value worth the risk -- while deliberately keeping it in Schedule I. That's not a footnote. The World Health Organization's own Expert Committee on Drug Dependence had produced findings that didn't support treating cannabis like heroin or its Schedule IV neighbors, and the CND still left the plant in the stricter of the two schedules it occupied. Something other than pharmacology was doing the deciding.

To understand where cannabis's international status is actually headed over the next decade, this piece leans on two real precedents rather than wishful extrapolation: the ongoing WHO review of coca leaf, which just produced its own Schedule I retention in December 2025, and Bolivia's withdrawal-and-re-accession maneuver, the only time any country has successfully carved out a domestic exception to a Schedule I restriction. The throughline connecting both cases to cannabis: a formal treaty amendment removing a plant from Schedule I has never once succeeded. Every real exit from prohibition's strictest tier has been a workaround. That fact should calibrate expectations for what "cannabis leaves Schedule I" could plausibly look like between now and the late 2030s.

The Two-Track System: WHO Recommends, Vienna Decides

The international drug control system runs on a split that rarely gets explained in plain terms, and it explains almost everything confusing about how slowly plant-based substances move through it. The WHO's Expert Committee on Drug Dependence is the only body the governing conventions actually authorize to conduct scientific review -- pharmacology, toxicology, dependence potential, epidemiological data on harm, and evidence of therapeutic use. ECDD does real technical work, the kind that takes years and produces documents running hundreds of pages. But ECDD cannot schedule or deschedule anything. It can only recommend.

Those recommendations go to Vienna, where the Commission on Narcotic Drugs -- a body of UN member states, not scientists -- votes on whether to adopt them. The CND is free to accept ECDD's findings, reject them outright, or quietly decline to act at all, and nothing in the treaty structure requires member states to justify a divergence from the science with anything more than a vote count. This is the structural chokepoint. It isn't specific to cannabis. Any plant or compound that WHO scientists conclude has been over-scheduled runs into the same wall: a political body with no scientific mandate holding veto power over a scientific body with no binding authority.

December 2020 is the clearest cannabis-specific case study. ECDD's review concluded cannabis didn't belong in Schedule IV alongside substances the international system treats as having essentially no redeeming medical value. The CND agreed, by a margin of 27 votes to 25 with one abstention -- razor thin, worth noting, not a consensus. Cannabis came out of Schedule IV. That was real progress, the first substantive change to cannabis's international status since the convention entered into force.

But the same vote left cannabis in Schedule I, the tier that still triggers the full weight of import/export licensing, production quotas, and the treaty's general presumption against non-medical, non-scientific use. ECDD's own findings hadn't suggested cannabis posed risks comparable to most other Schedule I substances -- codeine's parent compounds, cocaine's raw material coca, the opioids. Drug policy analysts who tracked the vote were blunt about the gap between the evidence and the outcome: the Schedule I retention reflected domestic political exposure for dozens of CND member states, not a scientific judgment about risk. That gap between what ECDD found and what CND did is the pattern to watch, because it repeats.

Coca's 2025-2026 Review: A Live Test of the Same Machinery

If 2020 gave us one data point on how this machinery handles a plant, the coca leaf review running through late 2025 and early 2026 gives us a second -- and it's remarkably similar. WHO's ECDD held its 69th session March 9-13, 2026, in Vienna, and member states ended up endorsing most of the committee's recommendations across a slate of substances under review. That's the headline version. The detail that matters more for this discussion is what happened in December 2025, a few months earlier: ECDD specifically recommended that coca leaf remain in Schedule I of the Single Convention.

The Transnational Institute, which has tracked coca and cannabis policy for decades, called the decision scientifically inconsistent with how the committee had handled other plant-based reviews. Coca leaf, chewed and brewed as tea across the Andes for thousands of years before the treaty criminalized it outright, has an evidentiary record on safety and traditional use that in some respects is stronger than cannabis's -- less acute toxicity data, a longer unbroken history of regulated indigenous use, and an existing domestic legal framework in Bolivia itself. If ECDD's own criteria were applied evenly, TNI's analysts argued, coca had at least as strong a case for movement as cannabis did in 2020. It didn't move.

What makes coca and cannabis worth examining side by side isn't that they're pharmacologically similar -- they aren't particularly. It's that they share the one feature that seems to matter most to how CND actually behaves: both are plants with documented traditional and indigenous use predating the treaty framework entirely, and both ended up in the strictest schedule anyway, and both have stayed there even after a scientific body flagged the mismatch. Two separate reviews, five years apart, involving two unrelated substances, produced the same structural outcome. That's not coincidence so much as evidence about the system itself. The political inertia holding Schedule I in place isn't really about cannabis's specific risk profile or coca's specific risk profile. It's a general reluctance within CND to make any move that implicitly concedes the original scheduling decisions were wrong, because that concession carries implications for a dozen other substances and for the credibility of the convention's founding judgments.

Why a Treaty Amendment Is the Only Clean Exit -- and Why It Doesn't Happen

Photo by epicioci via Pixabay.

Here's the part that tends to get glossed over in coverage of the 2020 cannabis vote: removing a substance from one schedule to another within the existing treaty text, as the CND did when it pulled cannabis out of Schedule IV, is a fundamentally different legal act than actually amending the treaty itself. Legal scholars who've written on this distinction are explicit about it. Full removal from Schedule I isn't achievable through the kind of schedule-transfer vote used in 2020. It requires formally amending the Single Convention's text -- not reinterpreting which annex a substance sits in, but rewriting the document.

That process is a different order of difficulty. A schedule transfer needs ECDD review and a CND majority vote, which is how cannabis moved out of Schedule IV. A genuine amendment needs a formal proposal, full WHO/ECDD review, and then a supermajority in CND -- a materially higher bar, and one deliberately built to resist being cleared casually, since treaty amendments were meant to be rare and considered events, not routine housekeeping.

Bolivia already tested this exact route, and the result is instructive. Bolivia proposed amending Article 49 of the Single Convention -- the specific clause that required parties to abolish coca leaf chewing within a set period of the treaty's entry into force, a provision that directly criminalized a centuries-old indigenous practice. The proposal was rejected. Enough parties objected that the amendment never cleared the threshold.

Zoom out further and the pattern holds across the convention's long life: no plant-based controlled substance has ever been removed from Schedule I through formal treaty amendment. Not coca, not cannabis, not any of the other botanicals the original drafters swept into the strictest tier based on the pharmacological understanding and political assumptions of that era. The front door has a perfect record, and it's a record of never opening.

That's precisely why every real piece of movement on these substances has come from somewhere else. Cannabis's 2020 Schedule IV exit used the schedule-transfer vote, not an amendment. Bolivia's eventual coca win, which we'll get into next, used a completely different mechanism that doesn't touch the treaty text at all. Both are side doors. The front door, as far as the historical record shows, doesn't open for plants.

The Bolivia Playbook: Withdraw, Re-Accede, Reserve

Photo by Tom D'Arby via Pexels.

After the Article 49 amendment attempt failed, Bolivia's government didn't try again through the same channel. It tried something structurally different, and this is the maneuver worth understanding in detail, because it's the only one on record that actually worked.

Bolivia formally withdrew from the Single Convention, effective January 1, 2012. The plan from the outset was to re-accede immediately afterward, but this time attach a reservation specifically protecting traditional coca leaf chewing within Bolivia's own territory -- carving out a domestic exception rather than asking the entire international community to rewrite the treaty's substance.

Treaty law gives other parties a window to block a reservation like this. Under the rules governing the convention, a reservation attached at re-accession is defeated only if one-third of the parties formally object within a set deadline -- in this case, roughly 62 of the 184 states party to the convention. That's a real threshold, not a formality; multilateral objections at that scale aren't trivial to organize, but they're also not impossible, especially for a change touching a UN drug treaty with decades of institutional momentum behind it.

By the January 10, 2013 deadline, only 15 of 184 parties had objected. Nowhere close to the one-third mark. Bolivia's re-accession, with its coca reservation intact, took effect February 10, 2013. It remains the only successful unilateral exit from a Schedule I restriction achieved through this withdraw/re-accede/reserve method since the convention came into force.

The limitation matters as much as the success. Bolivia's reservation protects coca leaf chewing inside Bolivia. It does nothing for coca grown or exported beyond Bolivia's borders, and it does nothing to coca's Schedule I status anywhere else in the world -- the leaf remains internationally restricted exactly as before, just with one country carved out domestically.

That's the realistic template for cannabis, if any country wanted to pursue formal treaty insulation rather than simply ignoring the mismatch between domestic law and treaty obligations. A mature cannabis-legal country could theoretically withdraw from the Single Convention and re-accede with a reservation covering its own legal adult-use and medical market, gaining a measure of formal legal cover for what dozens of jurisdictions are already doing informally. It wouldn't touch cannabis's global Schedule I status one bit. It would just mean one government stopped being in technical breach of a treaty it still otherwise honors everywhere else.

The US Rescheduling Saga Shows the Treaty Friction From the Inside

The US rescheduling process gives an unusually clear, close-up look at how treaty friction actually shows up in a government's internal paperwork, rather than staying abstract. On April 22, 2026, Acting Attorney General Todd Blanche signed the final order moving FDA-approved and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. That's the headline most outlets ran with. Buried in the same order, though, was language requiring import/export permits structured explicitly to stay consistent with Article 31 of the Single Convention -- the treaty provision governing how parties handle cross-border movement of scheduled substances.

That detail is the whole argument of this piece condensed into a single regulatory clause. The United States, rescheduling cannabis domestically through its own executive branch process, still had to write treaty-compliance language directly into the order. Even a purely domestic reclassification inside the world's largest cannabis economy couldn't avoid acknowledging that the country remains bound by a UN convention regardless of what 24-plus states have independently legalized within their own borders.

The broader rescheduling push -- the version that would more fully address adult-use markets rather than just the medical/FDA-approved slice -- moved through hearings from June 29 to July 15, 2026, with final briefs submitted by August 17. It hasn't resolved cleanly. On September 29, 2026, DEA Chief Administrative Law Judge Derek C. Julius stayed the proceeding to allow review of a new GAO report, with the government's response due October 13, 2026. As of this writing, that broader process remains unresolved -- an open thread rather than a closed chapter.

The lesson isn't that US rescheduling is failing. The narrower Schedule III move for medical cannabis went through. The lesson is that even inside a country with enormous market size, deep federal legal resources, and strong political will to reform its own cannabis law, treaty obligations under the Single Convention still surface as a live constraint that has to be drafted around, not simply waived. If the US -- with every domestic incentive to move fast -- still has to build Article 31 language into its own order, smaller economies with less legal capacity to spend face an even steeper version of the same problem.

What History Suggests About the Next 7-15 Years

Pulling the three threads together -- the 2020 cannabis vote, the 2025-2026 coca review, and Bolivia's withdrawal-and-re-accession maneuver -- produces a reasoned extrapolation rather than a confident date. Given a long record of zero successful Schedule I treaty amendments for any plant-based substance, a clean global removal of cannabis from Schedule I within the next 7 to 15 years is unlikely. That's not pessimism, it's pattern-matching against the only data the system has actually produced.

The more plausible path, modeled directly on Bolivia, is that one or more cannabis-legal countries with mature adult-use markets and enough diplomatic capital to spend attempt a withdraw/re-accede-with-reservation strategy, formally insulating their domestic markets from treaty-violation exposure the way Bolivia insulated coca chewing. Canada, Uruguay, Germany, or a US federal government further along its own reform path are the kind of candidates with both the market maturity and the diplomatic standing to try it.

The counter-case deserves equal weight, though, and it's a strong one. Bolivia's maneuver succeeded partly because coca reform carried broad international sympathy as indigenous cultural protection with fairly limited geopolitical stakes attached -- nobody's commercial interests were threatened by letting Bolivians chew coca leaf domestically. Cannabis carries far more commercial and geopolitical weight: the US federal government's own posture, International Narcotics Control Board scrutiny, and dozens of countries watching closely for precedent that might apply pressure back on their own domestic debates. A cannabis reservation attempt could plausibly draw far more than the 15 objections Bolivia faced -- possibly enough to clear the one-third threshold and actually block it, something that has never happened to a reservation of this kind but also has never been tested against a substance this commercially significant.

The December 2025 coca Schedule I retention is itself a bearish signal worth sitting with. Five years after cannabis's partial win, CND's underlying political caution hasn't loosened at all -- if anything it held firm against a case TNI's analysts argued was at least as strong as cannabis's.

There's a more speculative alternative path, too: continued erosion by accumulation rather than any formal maneuver at all. More countries simply legalize domestically in de facto breach of the convention -- as Canada, Uruguay, Germany, and more than two dozen US states already do -- until the treaty becomes unenforceable in practice even without ever being formally amended. There's real historical precedent for this pattern: international alcohol and tobacco control efforts from the early 20th century eventually diverged sharply from national law through exactly this kind of accumulated divergence, not through the underlying international agreements being rewritten.

The treaty bottleneck isn't a technicality that lawyers argue about while the real action happens elsewhere. It's the actual reason international cannabis commerce -- cross-border shipment of flower, extracts, even some research-grade material -- still operates in a gray zone in places where domestic law has been fully settled for years. A Canadian license holder and a German importer can both be operating in complete compliance with their own national statutes and still be navigating a treaty regime built around the assumption that cannabis has no legitimate use worth protecting.

For anyone tracking this space, the leading indicator worth watching isn't the next country to hold a legalization vote. It's whether any government files a formal withdrawal-and-reservation notice modeled on what Bolivia did with coca. That single filing would tell you more about where the international system is actually headed than ten more countries independently legalizing adult-use cannabis within their own borders ever could, because it would be the first real test of whether the Bolivia precedent scales to a substance with cannabis's commercial and political weight.

If the coca review is any guide, the UN system doesn't change because the conventions get rewritten. It changes because enough countries simply act as though the old rules don't apply to them, and the formal text quietly becomes less relevant than the accumulated weight of everyone ignoring it. That's a slower, messier story than a treaty amendment headline would be. It also happens to be the only story the historical record actually supports.